Overslaan en naar de inhoud gaan

 Wetenschapelijke artikelen

Tumor biology reflected by histological growth pattern is more important than surgical margin for the prognosis of patients undergoing resection of colorectal liver metastases.

Auteurs : Bohlok A, Inchiostro L, Lucidi V, Vankerckhove S, Hendlisz A, Van Laethem JL, Craciun L, Demetter P, Larsimont D, Dirix L, Vermeulen P, Donckier V
Jaar : 2023
Journal : Eur J Surg Oncol
Volume : 49
Pagina's : 217-224

ASO Visual Abstract: The Prognostic Value of Distinct Histological Growth Patterns of Colorectal Peritoneal Metastases-A Pilot Study.

Auteurs : El Asmar A, Demetter P, Fares F, Sclafani F, Hendlisz A, Donckier V, Vermeulen P, Liberale G
Jaar : 2023
Journal : Ann Surg Oncol

Pre-existing evidence and outcome of phase III trials in gastrointestinal oncology: a systematic review.

Auteurs : Bregni G, Trevisi E, Saude Conde R, Vanhooren M, Akin Telli T, Assaf I, Hendlisz A, Di Maio M, Sclafani F
Jaar : 2023
Journal : J Natl Cancer Inst

The Prognostic Value of Distinct Histological Growth Patterns of Colorectal Peritoneal Metastases: A Pilot Study.

Auteurs : El Asmar A, Demetter P, Fares F, Sclafani F, Hendlisz A, Donckier V, Vermeulen P, Liberale G
Jaar : 2023
Journal : Ann Surg Oncol

Regorafenib Induces Senescence and Epithelial-Mesenchymal Transition in Colorectal Cancer to Promote Drug Resistance.

Auteurs : Kehagias P, Kindt N, Krayem M, Najem A, Agostini G, Acedo Reina E, Bregni G, Sclafani F, Journe F, Awada A, Ghanem GE, Hendlisz A
Jaar : 2022
Journal : Cells
Volume : 11

Editorial: 'All you need is immunotherapy': a new treatment paradigm in sight for early-stage, mismatch repair-deficient/microsatellite instability high gastrointestinal cancers?

Auteurs : Sclafani F, Hendlisz A
Jaar : 2022
Journal : Curr Opin Oncol
Volume : 34
Pagina's : 379-381

Mind the target: human epidermal growth factor receptor 2 in colorectal cancer.

Auteurs : Saude Conde R, Rasschaert G, Bregni G, Hendlisz A, Sclafani F
Jaar : 2022
Journal : Curr Opin Oncol
Volume : 34
Pagina's : 382-388

First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study.

Auteurs : Lenz HJ, van Cutsem E, Luisa Limon M, Wong KYM, Hendlisz A, Aglietta M, García-Alfonso P, Neyns B, Luppi G, Cardin DB, Dragovich T, Shah U, Abdullaev S, Gricar J, Ledeine JM, Overman MJ, Lonardi S
Jaar : 2022
Journal : J Clin Oncol
Volume : 40
Pagina's : 161-170

Combined Metabolically Active Tumor Volume and Early Metabolic Response Improve Outcome Prediction in Metastatic Colorectal Cancer.

Auteurs : Woff E, Salvatore L, Marmorino F, Genovesi D, Critchi G, Guiot T, Ameye L, Sclafani F, Hendlisz A, Flamen P
Jaar : 2022
Journal : J Nucl Med
Volume : 63
Pagina's : 549-555

Regorafenib in combination with immune checkpoint inhibitors for mismatch repair proficient (pMMR)/microsatellite stable (MSS) colorectal cancer.

Auteurs : Akin Telli T, Bregni G, Vanhooren M, Saude Conde R, Hendlisz A, Sclafani F
Jaar : 2022
Journal : Cancer Treat Rev
Volume : 110
Pagina's : 102460

Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142.

Auteurs : André T, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M, Morse MA, van Cutsem E, McDermott R, Hill A, Sawyer MB, Hendlisz A, Neyns B, Abdullaev S, Memaj A, Lei M, Dixon M, Kopetz S, Overman MJ
Jaar : 2022
Journal : Ann Oncol
Volume : 33
Pagina's : 1052-1060

Circulating DNA in the neoadjuvant setting of early stage colon cancer.

Auteurs : Bregni G, Pretta A, Senti C, Acedo Reina E, Vandeputte C, Trevisi E, Gkolfakis P, Kehagias P, Deleporte A, Van Laethem JL, Vergauwe P, Van den Eynde M, Deboever G, Janssens J, Demolin G, Holbrechts S, Clausse M, De Grez T, Peeters M, DHondt L, Geboes K, Besse-Hammer T, Rothé F, Flamen P, Hendlisz A, Sclafani F
Jaar : 2022
Journal : Acta Oncol
Volume : 61
Pagina's : 1223-1229

JCOG0603: Are We Really Sure This Was a Negative Trial?

Auteurs : Saude Conde R, Bregni G, Saad E, Hendlisz A, Sclafani F
Jaar : 2022
Journal : J Clin Oncol
Volume : 40
Pagina's : 803-805

Results of a single-arm pilot study of (32)P microparticles in unresectable locally advanced pancreatic adenocarcinoma with gemcitabine/nab-paclitaxel or FOLFIRINOX chemotherapy.

Auteurs : Ross PJ, Wasan HS, Croagh D, Nikfarjam M, Nguyen N, Aghmesheh M, Nagrial AM, Bartholomeusz D, Hendlisz A, Ajithkumar T, Iwuji C, Wilson NE, Turner DM, James DC, Young E, Harris MT
Jaar : 2022
Journal : ESMO Open
Volume : 7
Pagina's : 100356

Isotoxic high-dose stereotactic body radiotherapy integrated in a total multimodal neoadjuvant strategy for the treatment of localized pancreatic ductal adenocarcinoma.

Auteurs : Bouchart C, Engelholm JL, Closset J, Navez J, Loi P, Gökburun Y, De Grez T, Mans L, Hendlisz A, Bali MA, Eisendrath P, Van Gestel D, Hein M, Moretti L, Van Laethem JL
Jaar : 2021
Journal : Ther Adv Med Oncol
Volume : 13
Pagina's : 17588359211045860

Sex and Regorafenib Toxicity in Refractory Colorectal Cancer: Safety Analysis of the RegARd-C Trial.

Auteurs : Vandeputte C, Bregni G, Gkolfakis P, Guiot T, Pretta A, Kehagias P, Senti C, Reina EA, Van Bogaert C, Deleporte A, Geboes K, Delaunoit T, Demolin G, Peeters M, DHondt L, Janssens J, Carrasco J, Holbrechts S, Goeminne JC, Vergauwe P, Van Laethem JL, Flamen P, Hendlisz A, Sclafani F
Jaar : 2021
Journal : Clin Colorectal Cancer
Volume : 20
Pagina's : 326-333

Age of Less than Forty Years Seems Not Be an Independent Factor for Poor Prognosis in Patients Undergoing Surgery for CRC.

Auteurs : Wagner A, Jacob N, Moreau M, Bouazza F, Bohlok A, Deleporte A, Sclafani F, Hendlisz A, Donckier V, Liberale G
Jaar : 2021
Journal : Journal of cancer research and therapeutic oncology
Volume : 9(2)
Pagina's : 9-15

Editorial: Radioembolization for metastatic colorectal cancer: towards maturity, at last?

Auteurs : Hendlisz A, Sclafani F
Jaar : 2021
Journal : Curr Opin Oncol
Volume : 33
Pagina's : 351-352

Anal squamous cell carcinoma: standards of care, new data and ongoing clinical trials.

Auteurs : Giunta EF, Bregni G, Hendlisz A, Sclafani F
Jaar : 2021
Journal : Curr Opin Oncol
Volume : 33
Pagina's : 372-377

Total neoadjuvant therapy for rectal cancer: Making sense of the results from the RAPIDO and PRODIGE 23 trials.

Auteurs : Giunta EF, Bregni G, Pretta A, Deleporte A, Liberale G, Bali MA, Moretti L, Troiani T, Ciardiello F, Hendlisz A, Sclafani F
Jaar : 2021
Journal : Cancer Treat Rev
Volume : 96
Pagina's : 102177